Edwin Johnson has over 20 years’ experience in CNS discovery and development, especially in the areas of neuroscience. With over 50 peer-reviewed publications and 10 patents, he has been extensively involved in numerous drug discovery programmes. In addition, he has also headed up teams working on drugs for the treatment of cognitive disorders, Parkinson’s disease and depression, taking them through clinical development. Since 2012, Edwin has headed the Stockholm Brain Institute and is the CNS lead at Karolinska Institutet Innovations, AB.
Professor Bickle obtained his PhD at the Biozentrum of the University of Basel, Switzerland, before moving to Cambridge, UK and later Lyon, France, where he was involved in the creation of a biotech company. Currently, he heads the screening facility of the Max Planck Institute of Molecular Cell Biology and Genetics (MPI-CBG) in Dresden, Germany, where he is developing chemical genomic cellular assays using automated microscopy, image analysis and multivariate statistics. He brings extensive technological experience to Cellectricon’s Advisory board, and will specifically support work with live cell high content screening, as well as data and image analysis.
Professor Svensson obtained her PhD at UC San Diego, where she also held a postdoctoral research position at the Department of Medicine. She subsequently moved on to Karolinska Institute, Stockholm, Sweden, where she today holds a position as Associate Professor and research group leader for Molecular Pain research at the Department of Physiology and Pharmacology. Her research is focused on investigating the role of neuroinflammation in the peripheral and the central nervous system, with particular focus on pain mechanisms in conditions with joint inflammation and autoimmunity, such as rheumatoid arthritis. Professor Svensson brings extensive disease area knowledge to the Advisory board and will be a key contributor in shaping Cellectricon’s chronic pain R&D strategy.